US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Aerovate Therapeutics, Inc. - Common Stock (NQ:AVTE)

2.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aerovate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke ↗
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs. 
Via Investor's Business Daily
News headline image
Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday? ↗
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary... 
Via Benzinga
News headline image
US Stocks Mixed; Dow Tumbles Over 100 Points ↗
 
Via Benzinga
Topics Stocks
News headline image
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses 
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Aerovate Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Recap: Aerovate Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Recap: Aerovate Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 ↗
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply during Friday’s session as the company reported FY23... 
Via Benzinga
Topics Stocks
News headline image
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 ↗
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023 ↗
 
Via Benzinga
News headline image
10 Short Squeeze Candidates: Getty Images, Genius Brands, MicroStrategy And More ↗
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
News headline image
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week ↗
Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the... 
Via Benzinga
News headline image
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week ↗
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
News headline image
Singing Machine, SurgePays And 3 More Short Squeeze Stocks That Could Soar This Week ↗
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
< Previous 1 2 3 4 5 Next >